URL has been copied successfully!
CHICAGO — If one word could describe research presented at this year’s American Heart Association scientific sessions, it might be “neutral.”
The meeting began with two blockbuster disappointments, hinted at in top-line results released weeks or months ago but detailed with unvarnished specificity Saturday morning. The ZEUS trial targeting inflammation showed no difference between the treatment and placebo arms. The HORIZON trial taking aim at lipoprotein(a) also revealed nearly identical results, whether participants were on or off the drug.
In other words, neutral.
Share this story:
